Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor, including the following tumor types:
• * Breast cancer
• * Non-small cell lung cancer
• * Prostate cancer
• * Bladder cancer
• * Gastroesophageal junction cancer
• * Ovarian cancer
• * Germ cell tumor
• Advanced or metastatic disease
• No effective curative therapy exists
• Evaluable disease
• * Measurable disease not required
• * Bone-only disease allowed
• No progressing brain metastases
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy \> 3 months
• Absolute neutrophil count ≥ 1,500/mm\^3
• Hemoglobin ≥ 9.0 g/dL
• Platelet count ≥ 100,000/mm\^3
• Bilirubin normal
• AST/ALT ≤ 2.5 times upper limit of normal
• Creatinine normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No serious intercurrent medical or psychiatric illness
• No serious active infection
• No gastrointestinal tract disease that would impair a patient's ability to take oral medication
• No history of significant cardiac disease, including any of the following:
• * Congestive heart failure
• * Symptomatic cardiac arrhythmias
• * Unstable angina
• No pre-existing peripheral neuropathy ≥ 2
• PRIOR CONCURRENT THERAPY:
• Any number of prior therapies allowed
• Prior paclitaxel, tyrosine kinase inhibitor therapy, or endothelial growth factor inhibitors allowed
• At least 14 days since prior and no concurrent CYP3A4 inducers or herbal or dietary supplements
• At least 7 days since prior and no concurrent CYP3A4 inhibitors
• At least 6 months since prior and no concurrent amiodarone
• More than 1 month since prior chemotherapy, radiotherapy, hormonal therapy, or investigational anticancer agents
• Concurrent continued use of gonadal suppression agents (i.e., goserelin acetate or leuprolide acetate) allowed
• No antacids 1 hour before and after study drug administration
• No concurrent retinoids
• No concurrent hormonal anticancer agent
• No other concurrent anticancer chemotherapy or investigational anticancer agents